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ABSTRACT 
 
 The present study was carried out to investigate  the  biochemical 
effects of Hypolip, anew simvastatin drug, on serum total cholesterol,low 
density lipoprotein ( LDL-C) ,and to assess its effects on liver function 
and muscle  haematological and histopathological finding. 
Twenty five Wister albino rats were divided into five groups. 
group (A) was fed basal diet only ( a control group) and the  other four 
groups (B, C, D and E) were fed 1% cholesterol-containing diet for 2 
weeks  to induce hypercholesterolemia. After two weeks,  groups (C, D 
and E) were orally administrated simvastatin at a dose rate of  10, 40, and 
80 mg/kg Bwt, respectively  for 4 weeks. Blood samples were taken 
avery two weeks to investigate serum total cholesterol, LDL-C and 
haematological parameters. liver function test and creatine kinase were 
also examined. 
Biopsy from liver and muscle were immediately taken after rats 
were slaughtered, and fixed in 10% neutral formalin, for histo-
pathological investigations. 
 There was a significant (P<0.05) increase in the serum Total-
cholesterol and (LDL-C) concentrations in groups B, C, D and E 
compared to the  control  A  after two weeks. 
The body weights  significantly (P<0.05) increased   in  the 
induced hypercholesterolemic rat after 4 weeks.  
 Two weeks after administration of hypolip, there was a significant  
(P<0.05) reduction  in LDL-C in groups C, D and E  compared to the  
control B.  There was a significant reduction on serum Total-cholesterol 
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concentration in group C only  compared with control group B.    
 After four weeks, there was a significant decrease in serum Total-
cholesterol in groups C, D and E  compared with control (B). There 
was,also, a significant reduction  in  LDL-c in groups D and E compared 
to the control   (B).  
Alanine amino transfers , aspartate amino transferase  and creatin 
kinase   significantly  increased in group E compared to the control B 
after 4 weeks. However , there were  no significant changes on levels of 
total protein, albumin and globulin in all treated groups through out the 
experimental period.  
After 4 weeks of  administration of hypolip haematological 
findings revealed no significant differences in red Blood Cell counts 
between treated groups  compared with the control group B. However, 
there was a significant reduction  in white blood cell counts in group D 
haemoglobin concentrations and PCV in group E compared to control 
group B. There were no significant changes on platelets concentrations in 
all  treated groups. 
  Histopathologically, in group B  liver  showed disorganization of 
hepatocytes and haemorrhagic. Muscle fibers were  fragmented, 
hyalinized and necrotic. In groups C and D,  the hepatocytes  were  
vaculated and sinusoids were dilated. The muscles were hyalized and 
fragmented but to a  lesser degree compared with those of  group B. In 
group E, the liver showed dilatation of sinusoid and congestion of the 
central vein. 
 ﺨﻼﺼﺔ ﺍﻷﻁﺭﻭﺤﺔ
 ﺍﻟﻬﻴﺒﻭﻟﺏ ﺤﺩﻴﺙ ﻤﻥ ﺍﻟﺴﻤﻔﺎﺴﺘﺎﺘﻴﻥ    ﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺍﺭﺴﺔ ﻟﺘﻘﺼﻲ ﺍﻷﺜﺭ ﺍﻟﺒﻴﻭﻜﻴﻤﻴﺎﺌﻲ ﻟﺩﻭﺍﺀ
 ﺍﻟﻜﺒـﺩ ﻭﺍﻟﻌﻀـﻼﺕ ﻭﻅـﺎﺌﻑ ﻗﻴﺎﺴﺎﺕ ﺍﻟﻜﻠﺴﺘﺭﻭل ﻭﺍﻟﺒﺭﻭﺘﻴﻨﺎﺕ ﺍﻟﺩﻫﻨﻴﺔ ﻤﻨﺨﻔﻀﺔ ﺍﻟﻜﺜﺎﻓﺔ   ﻋﻠﻲ
  .ﻐﻴﺭﺍﺕ ﺍﻟﻨﺴﻴﺠﻴﺔﻭﺍﻟﺘ ﻭﻅﺎﺌﻑ ﺍﻟﺩﻡ
ﺃﻋﻁﻴﺕ ( ﺃ)، ﺍﻟﻤﺠﻤﻭﻋﺔ ﻋﺎﺕﻗﺴﻤﺕ ﻟﺨﻤﺱ ﻤﺠﻤﻭﻭﻤﻥ ﻨﻭﻉ ﺍﻟﺒﻴﻨﻭ  (ﻓﺄﺭﺍﹰ 52)ﺍﺴﺘﻌﻤﻠﺕ 
ﺃﻋﻁﻴـﺕ ( ﺏ، ﺝ، ﺩ، ﻫـ)ﺍﻟﻭﺠﺒﺔ ﺍﻷﺴﺎﺴﻴﺔ ﻟﻠﻔﺌﺭﺍﻥ ﻓﻘﻁ ﻭﺴﻤﻴﺕ ﻤﺠﻤﻭﻋﺔ ﺘﺤﻜﻡ، ﺍﻟﻤﺠﻤﻭﻋﺎﺕ 
ﻤﻥ ﻤﺴﺤﻭﻕ ﺍﻟﻜﻠﺴﺘﺭﻭل  ﻟﻜل ﻜﺠﻡ ﻤﻥ ﺍﻟﻁﻌﺎﻡ ﻟﻤﺩﺓ ﺃﺴﺒﻭﻋﻴﻥ % ١ﺍﻟﻭﺠﺒﺔ ﺍﻷﺴﺎﺴﻴﺔ ﻤﻀﺎﻓﺎﹰ ﻟﻬﺎ 
  .ﺍﻟﺩﻡﺍﻟﻜﻠﺴﺘﺭﻭل ﻓﻲ  ﺯﻴﺎﺩﺓ ﻓﻲ ﺘﺭﻜﻴﺯ ﺍﺙﻹﺤﺩ ﻭﺫﻟﻙ 
ﺒﻭﺍﺴﻁﺔ ﺍﻟﻔﻡ ﺍﻟﻬﻴﺒﻭﻟﺏ ﺒﻌﻘﺎﺭ ( ﻫ، ﺩ، ﺠ)ﻤﺠﻤﻭﻋﺎﺕ ﺍﻟ  ، ﻋﻭﻟﺠﺕﺃﺴﺒﻭﻋﻴﻥ ﻤﻀﻲ  ﺒﻌﺩ 
  .ﻟﻤﺩﺓ ﺃﺭﺒﻌﺔ ﺃﺴﺎﺒﻴﻊ ﻋﻠﻲ ﺍﻟﺘﻭﺍﻟﻲ ﻤﻠﺠﻡ ﻤﻥ ﻭﺯﻥ ﺍﻟﺠﺴﻡ ٠٨ ﻭ ٠٤ ،٠١ﻜﻴﺯﺍﺒﺘﺭ
ﺃﺨﺫﺕ ﻋﻴﻨﺎﺕ ﺍﻟﺩﻡ ﻜل ﺃﺴﺒﻭﻋﻴﻥ ﻟﻘﻴﺎﺱ ﻤﺴـﺘﻭﻱ ﺍﻟﻜﻠﺴـﺘﺭﻭل ﻭﺍﻟﺒﺭﻭﺘﻴﻨـﺎﺕ ﺍﻟﺩﻫﻨﻴـﺔ 
ﻭﻅﺎﺌﻑ ﺍﻟﺩﻡ، ﻭﺃﺨﺫﺕ ﺃﻴﻀﺎﹰ ﻋﻴﻨـﺎﺕ ﺍﻟﻜﺒﺩ ﻭﺍﻨﺯﻴﻡ ﺍﻟﻜﺭﻴﺎﺘﻴﻥ ﻜﺎﻴﻨﺯ  ﻭﻗﻴﺎﺴﺎﺕ ﻭﻅﺎﺌﻑ ﻤﻨﺨﻔﻀﺔ ﺍﻟ
ﻭﻭﻀـﻌﻬﺎ ﻓـﻰ ﻓـﻭﺭﻤﻠﻴﻥ  ﺒﻌﺩ ﺍﻟﺫﺒﺢ ﻤﺒﺎﺸﺭﺓ ﻤﺭﻴﻀﺔﻟﻔﺤﺹ ﺍﻷﻨﺴﺠﺔ ﺍﻟ ﺍﻟﻜﺒﺩ ﻭﺍﻟﻌﻀﻼﺕ ﻤﻥ 
  .%1ﺘﺭﻜﻴﺯ 
ﺯﻴﺎﺩﺓ ﻤﻠﺤﻭﻅﺔ ﻓﻲ ﻤﺴﺘﻭﻱ ﻜﻠﺴـﺘﺭﻭل ﺍﻟـﺩﻡ  ﻡ ﺒﻌﺩ ﺃﺴﺒﻭﻋﻴﻥﺃﻅﻬﺭﺕ ﻨﺘﺎﺌﺞ ﺘﺤﺎﻟﻴل ﺍﻟﺩ
ﻤﻘﺎﺭﻨـﺔ ﺒﻤﺠﻤﻭﻋـﺔ ( ،، ﺩ، ﻫـ  ـﺠﺏ، )ﻓﻲ ﻤﺠﻤﻭﻋﺎﺕ  ﺍﻟﻜﺜﺎﻓﺔ ﻭﺍﻟﺒﺭﻭﺘﻴﻨﺎﺕ ﺍﻟﺩﻫﻨﻴﺔ ﻤﻨﺨﻔﻀﺔ
  (.ﺃ)ﺍﻟﺘﺤﻜﻡ 
ﻤﻘﺎﺭﻨﺔ ﻤﻘﺎﺭﻨـﺔ  (ﻫ، ﺩ،  ﺠﺏ، ) ﺯﻴﺎﺩﺓ ﻤﻠﺤﻭﻅﺔ ﻓﻲ ﻭﺯﻥ ﺍﻟﻔﺌﺭﺍﻥ ﻟﻠﻤﺠﻤﻭﻋﺎﺕ  ﻫﻨﺎﻙ
  (.ﺃ)ﺒﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﺤﻜﻡ 
ﻟﻤﺩﺓ ﺍﺴﺒﻭﻋﻴﻥ  ﺃﻭﻀﺤﺕ ﺍﻟﻨﺘﺎﺌﺞ  ﻭﺠﻭﺩ ﻨﻘﺼﺎﻨﺎ ﻤﻠﺤﻭﻅﺎ ﻓﻲ  ﺍﻟﻬﻴﺒﻭﻟﺏﺒﻌﺩ ﺇﻋﻁﺎﺀ ﻋﻘﺎﺭ 
ﻤﻘﺎﺭﻨﺔ ( ، ﺩ، ﻫـﺠ)ﻡ ﺨﺼﻭﺼﺎ ﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﺩﺨﻔﻀﺔ ﺍﻟﻜﺜﺎﻓﺔ ﻓﻲ ﺘﺭﻜﻴﺯ ﺍﻟﺒﺭﻭﺘﻴﻨﺎﺕ ﺍﻟﺩﻫﻨﻴﺔ ﻤﻨ
ix 
( ﺠ)ﻓﻰ ﺍﻟﻤﺠﻤﻭﻋﺔ  ﺍﻟﻜﻠﺴﺘﺭﻭل ﺘﻐﻴﺭﺍﺕ ﻓﻲ ﻤﺴﺘﻭﻱ ﻭﺒﻴﻨﻤﺎ ﻭﺠﺩﺕ، (ﺏ) ﻟﺘﺤﻜﻡﺍ ﺒﻤﺠﻤﻭﻋﺔ
   .ﻤﻘﺎﺭﻨﺔ ﺒﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﺤﻜﻡ 
ﻓﻲ ﺍﻟـﺩﻡ  ﻠﻜﻠﺴﺘﺭﻭلﻟﺍﻨﺨﻔﺎﻀﺎﹰ ﻤﻠﺤﻭﻅﺎﹰ  ﺤﺩﺙ ﺍﻟﻬﻴﺒﻭﻟﺏﺒﻨﻬﺎﻴﺔ ﺍﻷﺴﺒﻭﻉ ﺍﻟﺭﺍﺒﻊ ﻻﻋﻁﺎﺀ ﻭ
، ﻭﺍﻟﺒﺭﻭﺘﻴﻨﺎﺕ ﺍﻟﺩﻫﻨﻴـﺔ ﻤﻨﺨﻔﻀـﺔ ﺍﻟﻜﺜﺎﻓـﺔ (ﺏ)ﺔ ﺒﺎﻟﻤﺠﻤﻭﻋﺔ ﻤﻘﺎﺭﻨ( ، ﺩ، ﻫـﺠ)  ﻟﻤﺠﻤﻭﻋﺎﺕ
  (.ﺩ، ﻫـ)ﻤﺠﻤﻭﻋﺘﻲ 
 ﺍﻻﻨﻴﻥ ﺍﻤﻴﻨﻭ ﺘﺭﺍﻨﺴﻔﻴﺭﻴﺯ  ﻭﺍﺴﺒﺎﺭﺘﻴﺕ ﺍﻤﻴﻨﻭ ﺘﺭﺍﻨﺴﻔﻴﺭﻴﺯ  ﻭﺍﻟﻜﺭﻴﺎﺘﻴﻥ ﻜﺎﻴﻨﻴﺯ ﺴﺠﻠﺕ ﻨﺴﺒﺔ 
( ﻫـ  ـ) ﺎﺕﺨﺎﺼﺔ ﻤﺠﻤﻭﻋ  ـﺍﻟﻬﻴﺒﻭﻟﺏ ﻋﻁﺎﺀ ﻋﻘﺎﺭ ﺍﻤﻠﺤﻭﻅﺎﹰ ﺒﻨﻬﺎﻴﺔ ﺍﻷﺴﺒﻭﻉ ﺍﻟﺭﺍﺒﻊ ﻤﻥ  ﺍﺭﺘﻔﺎﻋﺎﹰ
ﺘﻐﻴﺭﺍﹰ ﻤﻠﺤﻭﻅﺎﹰ  ﺍﻟﺒﺭﻭﺘﻴﻥ ﺍﻟﻜﻠﻰ ﻭﺍﻟﺒﻴﻭﻤﻴﻥ ﻭﺍﻟﻘﻠﺒﻴﻭﻟﻴﻥ ﺘﺸﻜل ﻨﺴﺒﺔ ﻟﻡ . (ﺏ)ﻤﻘﺎﺭﻨﺔ ﻤﻊ ﻤﺠﻤﻭﻋﺔ 
  .ﺨﻼل ﻓﺘﺭﺓ ﺍﻟﺘﺠﺭﺒﺔ (ﺏ)ﻭﺍﻟﻤﺠﻤﻭﻋﺔ ( ﻫ،، ﺩ، ﺠ)ﺒﻴﻥ ﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﻤﻌﺎﻟﺠﺔ 
ﺍﻤﺎ ﻨﺘﺎﺌﺞ ﺘﺤﻠﻴل ﻭﻅﺎﺌﻑ ﺍﻟﺩﻡ ﻓﻘﺩ ﺍﻭﻀﺤﺕ ﻋﺩﻡ ﻭﺠﻭﺩ ﺘﻐﻴﺭ ﻤﻠﺤﻭﻅ ﻓﻰ ﻜﺭﻴـﺎﺕ ﺍﻟـﺩﻡ 
  .ﺍﻟﺤﻤﺭﺍﺀﺒﻴﻥ ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﻤﻌﺎﻟﺠﺔ ﻭﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﺤﻜﻡ 
ﺍﻟﺘـﻲ ﺃﻋﻁﻴـﺕ ( ﺩ)ﻜﺭﻴﺎﺕ ﺍﻟﺩﻡ ﺍﻟﺒﻴﻀﺎﺀ ﺘﻐﻴﺭﺍ ﻤﻠﺤﻭﻅﺎ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋـﺔ ﺴﺠل ﻤﺠﻤﻭﻉ 
  .ﺨﻼل ﻓﺘﺭﺓ ﺍﻟﺘﺠﺭﺒﺔ( ﺏ)ﻤﻠﺠﻡ ﻤﻘﺎﺭﻨﺔ ﺒﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﺤﻜﻡ  04ﺍﻟﻌﻘﺎﺭ ﺒﺠﺭﻋﺔ 
ﻓـﻲ    ﺍﻟﻨﺴﺒﺔ ﺍﻟﻤﺌﻭﻴﺔ ﻟﺤﺠﻡ ﺍﻟـﺩﻡ ﺍﻨﺨﻔﺎﻀـﺎﹰ ﻤﻠﺤﻭﻅـﺎﹰ ﻭ ﺴﺠل ﺘﺭﻜﻴﺯ ﺍﻟﻬﻴﻤﻭﻗﻠﻭﺒﻴﻥ  
  . ﺒﻨﻬﺎﻴﺔ ﺍﻟﺘﺠﺭﺒﺔ( ﺏ)ﻤﻘﺎﺭﻨﺔ ﺒﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﺤﻜﻡ ( ﻫـ)ﺍﻟﻤﺠﻤﻭﻋﺔ 
  .ﺔ ﺍﻟﺘﺤﻜﻡﺘﺸﻜل ﺍﻟﺼﻔﺎﺌﺢ ﺍﻟﺩﻤﻭﻴﺔ ﺘﻐﻴﺭﺍ ﻤﻠﺤﻭﻅﺎ ﻓﻰ ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﻤﻌﺎﻟﺠﺔ ﻭﻤﺠﻤﻭﻋ ﻟﻡ
ﻭﻭﺠـﻭﺩ ,ﻨﺯﻑ ﺩﻤـﻭﻯ  ﻋﺩﻡ ﻭﺠﻭﺩ ﺍﻨﺘﻅﺎﻡ ﺍﻟﺨﻼﻴﺎ ﺍﻟﻜﺒﺩﻴﺔ   ﺍﻷﻨﺴﺠﺔ ﻟﺤﻭﻅ ﻋﻨﺩ ﻓﺤﺹ
ﻭﻓـﻰ (.ﺏ)ﺍﻨﻔﺼﺎل ﻭﺘﻜﺴﺭ ﻓﻰ ﺍﻻﻟﻴﺎﻑ ﺍﻟﻌﻀﻠﻴﺔ ﻭﺘﻨﻜﺱ ﺯﺠـﺎﺠﻰ ﻭﻨﺨـﺭ ﻓـﻰ ﺍﻟﻤﺠﻤﻭﻋـﺔ 
ﻭﻓﻰ ﺍﻟﻌﻀﻼﺕ ﺘﻨﻜﺱ ﺯﺠـﺎﺠﻰ , ﺔ ﻭﻓﺭﺍﻏﺎﺕﻟﻭﺤﻅ ﺘﻭﺴﻊ ﺍﻟﺠﻴﺒﺎﻨﻴﺎﺕ ﺍﻟﻜﺒﺩﻴ( ﺩ,ﺝ)ﺍﻟﻤﺠﻤﻭﻋﺘﻴﻥ 
  (.ﺏ)ﻭﺘﻜﺴﺭ ﺍﻻﻟﻴﺎﻑ ﺍﻟﻌﻀﻠﻴﺔ ﻭﻟﻜﻥ ﺍﻗل ﺩﺭﺠﺔ ﻤﻘﺎﺭﻨﺔ ﺒﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﺤﻜﻡ 
 .ﺘﻭﺴﻊ ﺍﻟﺠﻴﺒﺎﻨﻴﺎﺕ ﺍﻟﻜﺒﺩﻴﺔ ﻭﺍﺤﺘﻘﺎﻥ ﺍﻟﻭﺭﻴﺩ ﺍﻟﻤﺭﻜﺯﻯ ﺠﻭﺩ ﻭ( ﻫ)ﻓﻰ ﺍﻟﻤﺠﻤﻭﻋﺔ ﻭ
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INTRODUCTION 
Lipid comprises a diverse range of molecules and to some 
extent is a relatively water-insoluble or no polar compounds of 
biological origin, including waxes, fatty acids, fatty-acid derived 
phospholipids, sphingolipids, glycolipids and terpenoids ( retinoids 
and steroids). Some lipids are linear aliphatic molecules, while others 
have ring structures. Some are aromatic, while others are not. 
Cholesterol is a lipidic, waxy steroid found in the cell 
membranes and transported in the blood plasma by lipoproteins of all 
animals (Emma, 2009). 
Lipoproteins are biochemical assemblies that contain both 
proteins and lipids. The lipids or their derivatives may be covalently 
or non-covalently bound to the proteins (Garrett and Grisham 1995). 
Disorders of lipid metabolism are manifested by elevation of 
the plasma concentration of the various lipid and lipoprotein fraction 
(Brown, 2001). 
Hypercholesterolemia is, higher concentrations of Low Density 
Lipoprotein and lower concentrations of functional High Density 
Lipoproteins are strongly associated with cardiovascular disease 
because these promote atheroma development in arteries (Brunzell, 
2008). 
Simvastatin belongs to stains, is a cholesterol-lowering drug. It 
reduces cholesterol by inhibiting an enzyme (Hydroxy Methyl 
Glutaryl - CoA reductase (HMG-COA) in the liver, which is 
necessary for the production of cholesterol. In the blood, statins lower 
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total and LDL (bad cholesterol) as well as triglycerides, but increase 
HDL (good cholesterol). Myopathy can be a serious adverse effect 
even an elevated creatine kinase (CK) (Chan et al., 2005).  
Simvastatin may include Serum aminotransferase elevations 
(Tuteja et al., 2008).  
The objective of this study is to investigate the ability of 
hypolip anew manufactured drug to lower plasma total-cholesterol and 
LDL- cholesterol to assess the drug for its effect on enzymes activities 
and on the liver and muscle. 
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CHAPTER ONE 
LITERATURE REVIEW 
 
1.1 Lipids 
Lipids are broadly defined as any fat-soluble (Lipophilic), 
naturally occurring  substance such as fats, oils, waxes, cholesterol, 
sterols, fat-soluble vitamins (such as vitamins A, D, E and K), 
monoglycerides, diglycerides, phospholipids and others (Michelle     
et al., 1993). 
Lipids in human plasma are transported in form of macro-
molecular complex term lipoproteins. A number of metabolic 
disorders that involve elevation in levels of any lipoprotein species are 
thus termed hyper-lipoproteinemias or hyperlipidemias. The term of 
hyperlipidemia don’t mean increased levels of triglycerides in plasma 
(Malloy and Kane ,2001).   
1.2 Lipoproteins 
    They are a biochemical assembly that contains both proteins 
and lipids. The lipids or their derivatives may be covalently or non-
covalently bound to the proteins (Garrett and Grisham 1995).  
1.3 Cholesterol  
        Is a lipidic, waxy steroid found in the cell membranes and 
transported in the blood plasma of all animals (Emma, 2009). It is an 
essential component of mammalian cell membranes, where it is 
required to establish proper membrane permeability and fluidity. In 
addition, cholesterol is an important precursor molecule for the 
biosynthesis of bile acids, steroid hormones, and is also important for 
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the metabolism of fat-soluble vitamins. Cholesterol is the principal 
sterol synthesized by animals, but small quantities are synthesized in 
other eukaryotes, such as plants and fungi. It is almost completely 
absent among prokaryotes, which include bacteria (Pearson, et al. 
2003). 
 1.3.1 Types of cholesterol 
1.3.2 Chylomicrons  
           Chylomicrons are formed in the intestine and carry 
triglycerides of dietary origin, unspecified cholesterol, and cholesteryl 
esters. They transit the thoracic duct to the Blood stream (Malloy       
and Kane 2001). 
1.3.3 Very low density lipoproteins (VLDL)  
They are secreted by the liver and exported triglycerides (TG) 
to peripheral tissues. The hydrolysis of TG by Lipoprotein Lipase 
(LPL) yield free fatty acids for storage in adipose tissue and oxidation 
in tissues such as cardiac and skeletal muscle. Depletion of 
triglycerides produces remnants, intermediate low density Lipoprotein 
IDL, some of which are endocytosed directly by liver and the 
remainders are converted to low density lipoprotein by further 
removal of TG mediated by hepatic lipase (Martin, 2006). 
1.3.4 Low density lipoproteins (LDL)  
LDL is a type of lipoprotein that transports cholesterol and 
triglycerides from the liver to the tissues. An increased level of LDL 
can also result from increased secretion of its precursor VLDL as well 
as from decreased LDL catabolism (Malloy and Kane 2001).  
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1.3.5 High density lipoproteins (HDL) 
They transported cholesterol from peripheral tissue to liver. 
Apolipoprteins of HDL, Apo (A) are secreted by the liver and 
intestine. HDL acquires cholesterol from peripheral tissue in a 
pathway that protects the cholesterol homeostasis of cells. In this 
pathway cholesterol is transported from the cell membrane by a 
transporter protein acquired by a small particle termed prebeta -1 
HDL, and then esterifies by Lecithin Cholesterol Acyl transferase 
(LCAT) enzyme, leading to the formation of larger HDL,  LDL, and 
chlomicron remnants with the aid of cholesterol ester (Bertram  and 
Katzung 2004). 
1.3.6 Lipoprotein (a) 
This is similar in lipid composition to LDL but has higher 
protein content. It is thought to be an independent cardiovascular risk 
factor; LP (a) is a genetic variation of plasma LDL. A high level of LP 
(a) is an important risk factor for developing atherosclerosis 
prematurely. The lesions in artery walls contain substances that may 
interact with LP (a), leading to the buildup of fatty deposits. (Martin, 
2006). 
1.4 Hypercholesterolemia 
Hypercholesterolemia there is, high concentrations of LDL and 
low concentrations of functional HDL which are associated with 
cardiovascular disease because they promote atheroma development 
in arteries (atherosclerosis). This disease process leads to myocardial 
infarction (heart attack), stroke, and peripheral vascular disease 
(Brunzell et al., 2008) LDL particles are often termed "bad 
cholesterol" because they have been linked to atheroma formation. On 
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the other hand, high concentrations of functional HDL, which can 
remove cholesterol from cells and atheroma, offer protection and are 
sometimes referred to as "good cholesterol". These balances are 
mostly genetically determined but can be changed by body build, 
medications, food choices, and other factors (Durrington, 2003). 
1.4.1 Atherosclerosis 
Is the condition in which an artery wall thickened as the result 
of a build up of fatty materials such as cholesterol. It is a syndrome 
affecting arterial blood vessels. It is a chronic inflammatory response 
in the walls of arteries, due to the accumulation of macrophage and  
white blood cells which has promoted by low density (especially small 
particle) lipoproteins. Without adequate removal of fats and 
cholesterol from the macrophages by functional high density 
lipoproteins (HDL). It is commonly referred to as a hardening or 
furring of the arteries. It is caused by the formation of multiple 
plaques within the arteries (Maton et al., 1993). 
1.4.2 Coronary heart disease 
This refers to the failure of coronary circulation to supply 
adequate circulation to cardiac muscle and surrounding tissue. It is the 
most common form of disease affecting the heart and an important 
cause of premature death (Boon et al., 2006). 
1.5 Lipid disorders 
 Disorders of lipid metabolism are manifested by elevation of the 
plasma concentration of the various lipid and lipoprotein fraction 
(total, LDL-C, VLDL, triglycerides, chylomicrons) and they result, 
predominantly, in cardiovascular disease. Classification of Hyper-
lipidemias includes two types of hyperlipidemia (Brown, 2001): 
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1. Primary hyperlipoproteinamia: is an inherited disorder and have          
5  types: 
a. Familial hypertriglyceridemia which is associated with 
lipoprotein lipase deficiency (LPL) .The low activity of 
LPL results in decreased removal of triglycerides (TG) 
from blood stream.  
b. Familial combined-hyperlipidemia is characterized by 
increased hepatic secretion of apolipoprtoein B-
containing VLDL and its conversion to LDL.  
c. Familial dysbeta lipoproteinemia there is a defect in a 
poliopeprotein E (the major ligand), that allows 
subsequent metabolism of remnant particles derived from 
VLDL and chylomicrons.  
d. Familial hypo-alpha lipoproteinemia in which the serum 
concentration of HDL is low, lead to coronary heart 
disease (CHD) and peripheral vascular disease.  
e. Familial hypercholesterolemia characterized by elevation 
of total cholesterol and LDL-cholesterol in plasma. In 
polygenic hyperlipdemia there is an increased level of 
total and LDL cholesterol, but in lesser degree, which 
results from over production of VLDL in the liver due to 
a combination of high dietary fat, obesity and individual 
susceptibility. It is the most common disorder in adult life 
with atherosclerosis accruing early but with lesser degree. 
2. Secondary hyperlipidemia, result from many factors including 
liver and biliary diseases, Obesity, hypothyroidism, diabetes 
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mellitus, diet, excess alcohol, renal disease and gluco-
corticosteroids drugs (Brown, 2001). 
1.6 Management of hyperlipidemia 
Any medical disorder that may lead to hyperlipieamia e.g. 
diabetes, hypothyroidism should be treated first (Jonsson, 2001). 
There are many methods by which hyperlipoproteinemia can be 
managed: 
1.6.1 Lipid- lowering plants 
A number of herbal medicines from plants and vegetables are 
used for controlling hyperlipidemia it's and related complications in 
patient (Dahanukar and Rege, 2000).  
Phytosterols either as plant sterols or plant stanols are natural 
cholesterol-like substances derived from plants used to prevent 
hyperlipidemia (Piironen et al., 2000).  
The main mechanism by which phytosterols reduce blood 
cholesterol is to inhibit cholesterol absorption in the small intestine. 
Therefore, the physical forms, carriers and solubilization of the 
phytosterols are important characteristics to determine the efficacy of 
phytosterols on cholesterol lowering (Berger et al., 2004).  
 Mukluk myrrh tree (Combphara mukluk), caused reduction in 
total cholesterol by (14-27%) and 22-30% of triglycerides levels, at 
seam time while HDL-cholesterol has increased by 20% (Satyavati, 
1988). 
The lipid lowering activity of Autocephalous indicus root 
extract has been studied in triton WR-1339 induced hyperlipidemia in 
rats. In this model, feeding with root extract (500 mg kg–1 b.w.) 
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lowered plasma lipids. Both lipid lowering and antioxidant activities in 
root extract of A. indicus could help prevention of hyperlipidemia and 
related diseases (Vishnu et al., 2008). 
1.6.2 Lipid-lowering Drugs  
In general, drugs act to reduce the concentration of cholesterol 
within hepatocytes, causing a compensatory increase in low-density -
receptors (LDL- R) on their surface, and increased uptake of 
Cholesterol-rich LDL particles from the blood stream. Members of 
this group Includes fibrate, niacin, bile acid sequestrant and satin.  
1.6.2.1 Fibrates  
Fibrates, hypolipidemic agents are a class of amphipathic 
carboxylic acids. They are used for a range of metabolic disorders, 
mainly hypercholesterolemia. Members of fibrate include 
benzafibrate, ciprofibrate, clofibrate, gemfibrozil and fenofibrate 
(Wikipedia, 2004). 
1.6.2.2 Mechanism 
Fibrates are agonists of the peroxisome proliferators activity 
receptor alpha (PPAR-α) in muscle, liver and other tissues. Activation 
of PPAR-α signaling result in increased β-oxidation in the liver, 
decreased hepatic triglycerides secretion, increased lipoprotein lipase 
activity (Wikipedia, 2004).                                           
1.6.2.3 Indications  
Fibrates are used as accessory therapy for hypercholesterolemia, 
usually in combination with statins. Clincal trials do support its use as 
a monotherapy agent. Fibrates increase HDL levels and decrease 
triglyceride levels (Wikipedia, 2004). 
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1.6.2.4 Side effects                      
Most fibrates can cause mild stomach upset and myopathy 
.Since fibrates increase the cholesterol content of bile, they increase 
the risk for gallstones. It also causes an increased risk of 
rhabdomyolysis (Wikipedia.org/wiki/fibrate”2004). 
1.6.3 Niacin 
Niacin (B3) is a water-soluble vitamin which prevents the 
deficiency disease pellagra. It is an organic compound with the 
molecular formula C6H5NO2.Itis a derivative of pyridine, with a 
carboxyl group (COOH) at the 3- position. Niacin is converted to 
nicotinamide and then to NAD and NADP in vivo. Niacin is a 
precursor to NADH, NAD, NAD+, NADP and NADPH, which play 
essential metabolic roles in living cells (Cox et al. 2000).  
1.6.3.1 Mechanism 
Niacin acts as inhibitor of VLDL secretion, this in turn 
decreasing production of LDL. Increased clearance of VLDL via 
Lipoprotein lipase pathway contributes to triglycerides reduction, thus 
the catabolic rate of HDL decreased (NCEP, 1985).            
1.6.3.2 Indications 
Niacin, like fibrates, lowering triglycerides by 20-50%. It may 
also lower LDL by 5-25% and increase HDL by 15-35% (NCEP, 
1985). 
1.6.3.3 Side effects 
Niacin may cause hyperglycemia, and may cause liver damage 
(NCEP, 1985). 
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1.6.4 Bile acid sequestrants 
Bile acid sequestrants are a group of medications used for 
binding certain components of bile in the gastrointestinal tract. They 
are generally classified as hypolipidemic agents. Three synthetic 
polymeric resins are members of this class namely Cholestyramine, 
Colestipol and Colesevelam (Wong, 2001). 
1.6.4.1 Mechanism 
Bile acid sequestrants are polymeric compounds which serve as 
ion exchange resins. They exchange anions such as chloride ions for 
bile acids; thus bind bile acids and sequester them from enterohepatic 
circulation (Wong , 2001). 
1.6.4.2 Indications 
Bile acids are biosynthesized from cholesterol, hence the 
disruption of bile acid reabsorption will decrease cholesterol level, 
particularly low density lipoprotein. Therefore, they may be used for 
the treatment of hypercholesterolemia and dyslipidmia (Wong , 2001). 
1.6.4.3 Side effect  
Since bile acid sequestrants are designed to stay in the gut, they 
generally do not have systemic side effects. However, they may cause 
problem in the gastrointestinal tract, such as constipation, diarrhea, 
and flatulence (Wong, 2001). 
1.6.5 Statins 
Statins are the treatment of choice for management of 
hypercholesterolemia because of their efficacy and safety profile. 
They also have an increasing role in managing cardiovascular risk 
patients with relatively normal levels of plasma cholesterol 
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(Schashtrer , 2004). This group included Atrovastatin, Cerivastatin, 
Fluvastatin, Lovastatin, Mevastatin, Pitavastan Pravastatin, 
Rosuvastatin and Simvastatin. 
1.6.5.1 Mechanism  
Commonly lipid-modifying therapies are statins which (HMG-
CoA reductase inhibitors). HMG-CoA reductase catalyses the 
conversion of HMG-CoA to mevalonate, the rate-limiting step in de 
novo cholesterol synthesis. Competitive inhibition of this enzyme by 
the statins decreases hepatocyte cholesterol synthesis. The associated 
reduction in intracellular cholesterol concentration induces LDL-
receptor expression on the hepatocyte cell surface, which results in 
increased extraction of LDL-C from the blood and hence decreased 
circulating LDL-C concentration (Hobbs et al., 1992).can also reduce 
levels of atherogenic lipoproteins by inhibition of hepatic synthesis of 
apolipoprotein B100 and a reduction in the synthesis and secretion of 
triglyceride-rich lipoproteins (Grundy, 1998) (Fig. 1). 
1.6.5.2 Indications 
Statins, the most potent cholesterol-lowering agents available, 
lower LDL cholesterol. This translates in a 60% decrease in the 
number of cardiac events and a 17% reduced risk of stroke (Liu et al., 
2006).  
1.6.5.3 Side effects 
Statins are generally well-tolerated and have only two major 
side effects. That occurs, relatively rarely, raised liver enzymes and 
skeletal muscle damage. More serious but rare reactions include 
myositis and myopathy, with the potential for rhabdomyolysis 
(Marcoff and Thompson 2007). 
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Fig. (1): The HMG-CoA reductase pathway, which is blocked by 
statins via inhibiting the rate limiting enzyme HMG-CoA 
reductase 
File: HMG-CoA reductase pathway.png 
From Wikipedia, the free encyclopedia 
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Combining any statin with a fibrate, another category of lipid-
lowering drugs increases the risks for rhabdomyolysis (Graham, 
2005). Consumption of grapefruit or grapefruit juice inhibits the 
metabolism of statins; furanocoumarins in grapefruit juice inhibit the 
cytochrome P450 enzyme CYP3A4, which is involved in the 
metabolism of most statins (however it is a major inhibitor of only 
lovastatin, simvastatin and to a lesser degree atorvastatin) (Kane and 
Lipsky, 2000). 
1.6.6 Hypolip (Simvastatin) 
It is a hypolipidemic drug belonging to the class of "statins". It 
is used to control hypercholesterolemia (elevated cholesterol levels) 
and to prevent cardiovascular disease. Simvastatin is a synthetic 
derivate of a fermentation product of Aspergillums terreus. 
Simvastatin is a cholesterol-lowering medication that blocks the 
production of cholesterol) in the body. Simvastatin reduces low-
density lipoprotein (LDL) cholesterol and total cholesterol in the 
blood. Lowering cholesterol can help prevent heart disease and 
hardening of the arteries, conditions that can lead to heart attack, 
stroke, and vascular disease.  
1.6.6.1 Description 
 Simvastatin is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-
hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4hydroxy-6-oxo-2H-pyran-
2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1α,3α,7β,8β(2S*,4S*),-8aββ]]. 
Simvastatin is a white, no hygroscopic,  crystalline  powder  that  is 
practically insoluble in water and freely soluble in chloroform, 
methanol and ethanol. The empirical formula of simvastatin is 
C25H38O5 and its molecular weight is 418.57 (Fig. 2). 
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Simvastatin 
 
 
Figure (2): Chemical Structure of Simvastatin 
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1.6.6.2 Pharmacokinetics 
Simvastatin is a lactone that is readily hydrolyzed in vitro to the 
corresponding B-hydroxyacid,a potent inhibitor of HMG-CoA 
reductase.Following an oral dose of tables simvastatin in man 13% of 
the dose was excreted in urine and 60% in feces.Both simvastatin and 
B- hydroxyacid metabolite are highly bound plasma protein. The 
major active metabolites of simvastatin present in plasma are the B-
hydroxyacid of simvastatin and its 6'-hydroxy, 6'-hydroxymethyl, and 
6'-exomethylene derivatives. 
1.6.6.3 Indications 
Simvastatin is indicated to reduce elevated total-cholesterol, 
LDL-cholesterol, Apo B, and TG, and to increase HDL-C in patients 
with primary hypercholesterolemia, treat patients with primary 
dysbetalipoproteinemia and reductions in risk of CHD mortality and 
cardiovascular events. 
1.6.6.4 Side effects 
Common side effects (>1% incidence) may include abdominal 
pain, diarrhea, indigestion, and a general feeling of weakness. Rare 
side effects include joint pain, memory loss, and muscle cramps (Gen,  
2007). Serum aminotransferase elevations are a commonly known 
adverse effect of simvastatin therapy (Tuteja, 2008). Myopathy can be 
a serious adverse event elevated creatine kinase (CK) (Chan et al., 
2005).  
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Experimental Animals                                                                                           
Twenty five healthy Wister albino rats of both sex weighing 
from (100-230gm) were supplied by Medicinal Aromatic Plant 
Research Institute (MAPRI), National Research center. They were 
housed under standard conditions within the premises of (MAPRI) 
and have free access to water and standard diet. They were left for 7 
day as and adaptation period.                                                                                           
2.1.2 The diet  
The basal diet which provided the nutritional requirements to 
rats was composed    of the following constituents (per Kg): 
Wheat flour                660 
Dry meat                   147 
Plant oil                   120 
Sodium chloride       3g 
2.1.3 Hypolip (Simvastatin) 
The powder form of the drug was supplemented by Blue Nile 
Pharmaceutical Factory. The different concentrations of the drug were 
prepared by dilution of the powder .The stock solution was prepared 
by dissolving 100mg simvastatin in 100ml distil water, The solutions 
were stored in refrigerator to be used at the time of administration. 
The concentration of simvastatin was 1mg/ml, and then the doses 
were calculated according to rat’s weight. 
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2.1.4 Cholesterol 
The powder form of 1% cholesterol was supplemented from 
Lab Line Company and was added to the rat’s basal diet to induce 
hypercholesterolemia according to the method of Birkner et al., 
(2009). 
2.1.5 Experimental Design                                                                                        
The rats were divided randomly into five groups (5/rats). Group 
A was left as control, group B, C, D and E were fed a diet containing 
1% cholesterol for 2 weeks only so as to induce hyper chlesterolemia 
.The groups C and D administrated simvastatin using nasogastric tube 
daily at concentration rate of 10, 40 and 80 mg / kg Bwt respectively 
for 30 days. 
2.1.6 Parameters 
  Hematological investigation included red blood cells (RBCs) 
count, white blood cells (WBCs) count, packed cell volume (PCV) 
and hemoglobin concentration (Hb).  
Serum investigation included, total serum protein concentration, 
albumin concentration, globulin concentration ,serum total 
cholesterol, low density lipoprotein, alanine amino transferase (ALT) 
activity aspartate amino transferase (AST) activity and creatine kinase 
(CK) activity. Samples were taken from liver, and muscle at the end of 
the experimental period and fixed in 10% natural buffered formalin 
for histopathological investigation.  
2.2 Methods                                
 2.2.1 Blood collection 
Blood was collected by puncturing retro-orbital plexus,        
with heparinized capillary tube, and allowed to clot at room 
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temperature for 30 minutes then centrifuged (Hittich EBA 35) at 300r 
–pm sera were separated and stored at –20oC until for biochemical 
investigation.  
 Blood constituent were determined using Sysmex ®Kx-21N. It 
was fully automated computerized. The KX-21N employs three 
detector blocks and two kinds of reagent for blood analysis. The WBC 
count is measured by WBC detector block using the detector cont 
detection method. The RBC count and platelets are taken by the RBC 
detector block The HGB detector block measures the hemoglobin 
concentration using the non-cyanide hemoglobin method.  
2.2.2 Serum analysis 
Sera constituents were determined using Roche Diagnostics 
Hitachi 902 Analyzer. It was fully automated, computerized and 
performs potentiometric and photometric assay.  
2.2.2.1 Measurement of serum total cholesterol (TC) 
Reagents 
Reagent composition:     Final concentrations  
Good’s Buffer PH6.7    80 mmol/L 
Phenol       5mmol/L 
4. Aminoantipyrine    0.3mmol/L 
Cholesterol esterase (CHE)   ≥ 200 V/L 
Cholesterol oxidase (CHO)   ≥ 50 V/L 
Peroxidase (POD)               ≥  3 k/L 
Principle:  
Cholesterol ester + H2O   CHE     cholesterol + fatty acids 
Cholesterol + O2   CHO      cholesterol -3-one + H2O2 
2H2O2+phenol +4Aminoantipyrine  POD  Quinoneimine   +4H2O 
                                                                         (Pink color) 
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The intensity of the pink/red color of the Quinoneimine is 
proportional to the cholesterol concentration in the sample (Roeschlau 
et al., 1974). The test has been developed to determine cholesterol 
concentrations with in a measuring range from 3-800 mg/dL (on 
Hitachi). 
 Procedure: 
 500 µL of plasma samples were put in Hitachi sample cups. 
The sample cups were entered in a specific place on Hitachi 902 and 
then the parameters to be measured were selected from the touch 
screen and registered automatically. Thereafter the machine was put 
on and the results were printed in ten minutes. Hitachi 902 machine 
adds 500µL from sample and reagent, and the reaction proceeds 
automatically. 
Calculations:  
The analyzer automatically calculates the analyze concentration 
of each sample and the results appear directly on the LCD touch 
screen at the end of the reactions between the samples and reagent. 
Cholesterol concentration mg/dl = O.D of the test  X Standard concentration O.D of the standard 
 
2.2.2.2 Measurement of serum low Density Lipoprotein (LDL)  
Reagent Composition: 
Reagent (1)            final concentration 
Good’s Buffer PH6.8      25 mmol/L 
Cholesterol Esterase (CHE)     5000 U/L 
Cholesterol Oxidase (CHO)      5000 U/L 
N-(2-Hydroxy-3-sulfopropyl)-3,5dimethoxyaniline (HDAOS) 
                                                                                   0.64 mmol/L 
Castalase                                                                        1000 KU/L     
 
21 
 
Reagent (2)        
Good’s Buffer PH 7.0    25mmol/L 
4Aminoantipyine      3-5 mmol/L 
Peroxidase (POD)     20KU/L 
Soium azide 
Principle: 
In this method, non-LDL lipoproteins are enzymatically 
processed, while LDL is selectively protected in the first incubation 
step with reagent (I). In the second step, LDL is released and 
selectively determined (Bachorik, 1997). 
LDL + protecting reagent (reagent 1)                     protected LDL. 
HDL, VLDL, chylomicrons     CHE, CHO    cholestenone H2O2 
HDL.C   CHE, CHO    cholestenone + H2O2 
H2O2 + 4.Aminoantipyrine+H-DAODS   POD (blue colored complex) 
The test has been developed to determine LDL concentrations 
within a measuring range from 1-400 mg/dl. 
Procedure:  It is similar to that used in cholesterol measurement 
Calculation:  
It is similar to that used in cholesterol measurement                                             
2.2.2.3 Alanine amino Transferase (ALT) 
This enzyme is formerly known as Glutamate Pyruvate 
Transaminase (GPT). The assayed of GPT as recommended by the 
international federation of clinical chemistry (IFCC) (Clin. et al., 
1980). 
Principle:                                                                                                
NADH is oxidized to NAD; the resulting decrease in 
absorbance at 340 nm is directly proporational to the activity of GPT 
in the sample. 
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L – alanine + 2- oxoglutarate    GPT      pyruvate + L-Glutamate 
Pyruvate + NADH + H   LDH      L- lactate + NAD 
NAD    = Nictinamid Adenine Dinucleotide 
NADH =Reduced NAD 
LDH = Lactate Dehydrogenase 
GPT = Glutamate-Pyruvate Transaminase 
Procedure:                                                                                                                       
Two ml of alanine amino transferase and control were pipetted 
into two separated test tubes and were put into control and calibration 
positions in to Hitachi apparatus automatic analyzer model 902. 
Calibration was according to the identification number (ID) for the 
alanine amino transferase. The reading at wave length 902 nm the 
GPT was measured in (U/L)                                                                 
2.2.2.4 Aspartate amino transferase (AST)  
Glutamic oxaloacetate (GOT) in sera was measured by 
international Federation Clinical Chemistry (Clin et al., 1980).                                      
Principle: 
NADH is oxidized to NAD; the resulting decrease in 
absorbance at 340 nm is directly proportional to the activity of GOT in 
the sample. 
L – Aspartate + 2- oxoglutarate    G0T      Oxaloacetate + L-Glutamate 
Oxaloacetate +NADH  +H     MDH      L-malate +NAD 
GOT=Glutamate Oxaloacetate Transaminase  
MDH=Malate Dehydrogenase  
NAD=Nicotinamide Adenine Dinucleotid  
NADH= reduced NAD 
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Procedure:  
Two ml of aspartate amino transferase and control were 
pipetted into two separated test  tubes and were put into control and 
calibration positions into Hitachi apparatus automatic analyzer model 
902 .Calibration was according to the identification number (ID) for 
the aspartate amino transferase. The reading at wave length 902 nm 
.the AST was measured (IU/L). 
2.2.2.5 Creatine Kinase (CK):   
The activity of (CK) was measured by an optimized                         
DGKC/IFCC (Wurzburg et al., 1977).  
Principle:  
Creatine  phosphate + ADP CK  creatine  + ATP 
ATP+ Glucose   HK   ADP+ Glucose 6-p (G-6-P) 
G-6-p+NADP G-6-P-DH Gluconate -6-p+NADH+H  
CK= Creatine kinase. 
HK= Hesokinase. 
G-6-P-DH=Glucose -6-phosphate dehydrogenase. 
Procedure: 
          Two ml of creatine kinase and control were pipetted into 
separated test tubes and were put into control and calibration positions 
into Hitachi apparatus automatic analyzer. Calibration was according 
to the identification number (ID) for the creatine kinase. The reading 
at wave length 902 nm the CK was measured in (U\L).  
2.2.2.6 Total protein determination  
The determination of total protein concentration was done 
according to Biuret method described by (Johnson et al., 1999). 
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Principle: 
The principle of this total protein assay is the biuret reaction. In 
alkaline solution, cupric ions react with all compounds with two 
amide or peptide bonds linked either directly or through an 
intermediate carbon atom to form a violet colored complex.  
Procedure: 
        Two ml of Protein and control were pipetted into two separated 
test tubes and were put in to control and calibration positions into 
Hitachi apparatus automatic analyzer. Calibration was according to 
the identification number (ID) for the protein. The reading at wave 
length 909nm the total protein measured in (g\dll). 
2.2.2.7 Albumin  
 Albumin concentration was measured using Bromo Cresole 
Green (BCG) method described by (Doumas et al., 1975). 
Principle: 
 The procedure is based on the binding of brom cresol green 
(BCG) to albumin. The intensity of the blue-green color produced in 
the reaction is proportion to the concentration of albumin in the 
sample.                                                                 
Procedure: 
 Two ml of albumin and control were pipetted into two 
separated test tubes and were put in to control and calibration 
positions into Hitachi apparatus automatic analyzer. Calibration was 
done according to the identification number (ID) for the albumin. The 
reading at wave length 902 mn. Protein was measured in (g/dl).                                     
2.2.2.8 Globulin  
 This parameter is obtained by subtracting albumin concentra-
tion from total protein concentration. 
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2.2.2.9 Total bilirubin 
Principle 
 Total bilirubin reacts with diazotized dichloroaniline to form 
a colored Azocomoned (Tolman and Rej 1999). 
Procedure: 
 Two ml of bilirubin and control were pipetted in to two 
separated test tubes and were put into control and calibration positions 
into Hitachi apparatus automatic analyzer model 902 . Calibration was 
according to the identification number (ID) for the bilirubin. The wave 
length 902 nm the bilirubin was measured in (mg/dl).                                                     
2.3 Histopathological methods 
At the end axepariment rats were slaughtered, specimens from 
Liver and Muscle. Were immediately removed and fixed in 10% 
neutral Formalin (sodium hydrogen 6.5 gm/L and sodium 
dehydrogenate 4.0 gm/L0. They were embedded in paraffin wax, and 
sectioned at 5µm and stained by Haemotoxyline and Eosin (H & E) 
using ( Druray and Wallington, 1980).  
2.4 Statistical analysis   
The obtained data were subjected to one-way analysis of 
variance (ANOVA) by Completely Randomized Design (CRD), and 
the data were presented as means ±standard errors (SE) according to 
(MSS, 2003). 
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CHAPTER THREE 
RESULTS 
 
3.1 Induction of hypercholesterolemia 
 The effects of feeding 1% cholesterol diet on plasma total 
cholesterol and LDL-c in albino rats for 2weeks is presented in table 
(1). 
 The plasma levels of Total cholesterol (T.C) concentrations 
showed a highly significant increase (P<0.01) in groups (B, C, D and 
E) fed 1% cholesterol diet compared to control (A) after two weeks of 
experiment. 
The plasma levels of Low Density Lipoprotein- cholesterol 
(LDL-C) showed highly significant increase (P<0.01) in groups (B, C, 
D and E) fed 1% cholesterol diet compared to control (A) after 2 
weeks. 
3.2 Body weight 
The mean changes on body weight of rat feed 1%cholesterol 
diet and the control group were shown in table (2). 
There were significant differences (P<0.05) between control 
and rats feed 1% cholesterol diet throughout experimental period in 
the body weight. The weight of rats fed cholesterol was higher by 
15.8, 20%. 
3.3 Serum lipid profiles 
3.3.1 Total cholesterol (T.C) 
The effects of oral administration of simvastatin on T.C in an 
induced hypercholesterolemic rat are presented in table (3). 
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Table (1): Mean changes in Total cholesterol and Low Density 
Lipoprotein cholesterol in an induced hyper-
cholesterolemic rat. 
 
 
 
 
 
 
Values are presented as Means ± SE (standard errors)  
   *                       (P<0.01)   
Group    (A): Control (fed normal diet only). 
Groups (B-E): 1%cholesterol-containig died. 
 
 
 
 
 
 
Period 
(weeks) Groups 
Total cholesterol 
(mg\dl) 
LDL-c 
(mg\dl) 
           2    A 52.75 ± 3.6 12.07±1.7 
 B 155.33 ± 7.2* 91.60±4.8* 
 C 122.50 ± 5.5* 69.50±4.2* 
 D 193.33 ±8.1* 132.97±6.7* 
 E 128.00 ± 5.7* 71.58±4.2* 
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Table (2): Mean changes in body weight in an induced hyper-
cholesterolemic rat. 
  
 
 
 
 
 
 
 
Values are presented as Means ± SE (standard errors)   
  *                            (P<0.05)      
Group   (A):  control (Fed normal diet only)  
Groups (B-E): 1% cholesterol containing died.  
 
 
 
 
 
 
Groups Initial Body weight (gm) 4week 
A 138±5.25 164.5±6.40 
B 138±5.25 172.5±6.56* 
C 137±5.23 171.5±6.54* 
D 138±5.25 172.5±6.56* 
E 138±5.25 172.5±6.56* 
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Table (3): Mean changes in T.C and LDL-c in an induced hyper-
cholesterolemic rat after 2 and 4 weeks treated with 
Simvastatin: 
 
Values are presented as Means ± SE (standard errors)  
 Significant             *    (P<0.05)   
Highly significant    **   (P<0.01) 
Groups: 
 (B):  Fed cholesterol-containing diet 1% only. 
(C):  Fed cholesterol-containing diet 1% &received 10 mg/kg simvastatin. 
(D): Fed cholesterol-containing diet 1%& received40 mg/kg simvastatin. 
(E):  Fed cholesterol-containing diet 1%& received 80 mg/kg simvastatin 
 
 
 
 
 
 
 
Period 
(weeks) Groups T.C(mg\dl) LDL-c(mg\dl) 
2 B 79.75  ±4.5 41.47±3.2 
C 68.75 ±4.1* 26.95±2.6* 
D 84.00 ± 4.6 22.10±2.4* 
E 77.00 ± 4.4 25.43±2.5* 
4 B 107.7  ±5.2 46.47±3.4 
C 86.33 ± 5.4* 39.47±3.6 
D 82.00 ± 4.5* 31.00±2.9* 
E 55.67 ± 3.7** 33.80±3.4* 
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There was a significant decrease (P<0.05) in plasma Total 
Cholesterol (T.C) in group(C) received 10 mg/kg Bwt of Simvastatin 
(68.75±4.1 mg\dl) compared to control (B) (79.75±4.5 mg/dl) after 2 
weeks administration of Simvastatin. However, there were no 
significant changes in groups (Dand E) received 40, 80 mg/kg 
compared to control (B). Mean while there was a highly significant 
reduction (P<0.01) on plasma T.C in group (E) received 80mg/kg Bwt 
of Simvastatin (55.67±3.7 mg/dl) compared to control (B) (107.7 
±5.2mg/dl) after 4 weeks administration of Simvastatin. There was 
significant reduction in group (C and D) which received 10, 40 mg\Kg 
Bwt respectively compared to control (B). 
3.3.2 Low Density Lipoprotein-cholesterol (LDL-c)  
The mean changes on plasma LDL-c in an induced hyper-
cholesterolemic rat treated with of simvastatin is presented in table 
(3). 
There was a significant reduction(P<0.05)   in plasma LDL-c in 
groups (C, Dand E) that received 10, 40,80mg/kg Bwt of simvastatin 
(26.95±2.6, 22.10±2.4, 25.43±3.2mg\dl) respectively compared to 
control (B) (41.47±3.2mg\dl) after 2 weeks administration of 
simvastatin. However after 4 weeks, there was a significant reduction  
(P<0.05) on LDL-c in groups (D and E) while  received 40, 80 mg/kg 
Bwt simvastatin (31.00± 2.9, 33.80±3.4 mg/dl) compared to control 
(B) (46.47±3.4 mg\dl) but there were no significant differences on 
LDL-c in groups (C) received 10mg/kg Bwt of simvastatin. 
3.4 Changes in serum constituents 
 The effects of simvastatin on concentration of activity of 
alanine transaminase, aspartate amino transferase and creatine kinase 
are given in table (4). 
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Table (4): The mean changes in serum constituents in an induced 
hypercholesterolemic rat after 2 and 4 weeks  treated with 
simvastatin  
    
 
Values are presented as Means ± SE (standard errors)  
*              (P<0.05)   
Groups: 
 (B):  Fed cholesterol-containing diet 1% only. 
(C):  Fed cholesterol-containing diet 1% &received 10 mg/kg  Simvastatin. 
(D):  Fed cholesterol-containing diet 1%& received 40 mg/kg Simvastatin. 
(E): Fed cholesterol-containing diet 1%& received 80 mg/kg Simvastatin 
 
 
 
 
 
Duration 
(week) Groups ALT(U/L) AST (U/L) CK(U/L) 
2 B 
C 
D 
E 
16.06±4.1 
15.81±3.9 
15.12±3.8 
22.14±4.7* 
48.62±13.7 
35.62±5.9 
35.43±5.9 
69.75±8.3* 
21.0±4.5 
11.5±3.3* 
22.0±4.6 
 
4 B 
C 
D 
E 
14.68±3.8 
15.75±3.9 
12.62±3.5 
21.18±3.7* 
44.43±6.6 
45.43±6.6 
47.12±6.8 
49.75±6.9* 
886.0±29.9 
811.0±28.4 
462.0±21.49* 
2300±47.95* 
32 
 
 
 There was a significant increase (P<0.05) between control (B) 
and group (E) with treated 80mg/kg Bwt of simvastatin on Alanine  
amino transferase (ALT) activity after 2 and 4 weeks.  
 On the other hand there were no significant changes between 
control and treated groups at doses of 10, 40 mg\kg Bwt of 
simvastatin.  
 There was a significant increase (P<0.05) between control (B) 
and group (E) treated 80mg/kg Bwt on aspartate amino transferase 
(AST) activity after 2 and 4 weeks.           
 There was a significant decrease (P<0.05) on serum (CK) 
activity in group (C) treated with 10 mg/kg Bwt and control group (B) 
after 2weeks.  
 However a significant reduction (P<0.05) on serum (CK) 
activity in group (D) treated with 40 mg/kg Bwt and control group (B) 
after 4 weeks. 
 There was a significant increase (P<0.05) between control (B) 
and group (E) treated 80mg/kg Bwt simvastatin on Creatin kinase.  
3.5 Other Biochemical Tests 
 The effects of various doses of simvastatin on concentration of 
Total bilirubin, Total protein, Albumin and Globulin are given in table 
(5).          
 There were non significant differences on total bilirubin, total 
protein, albumin and globulin concentrations between treated rats (C, 
D and E) and control (B) through out experimental period. 
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Table (5): The mean changes in Liver Function Tests in an induced 
hypercholesterolemic rat after 2 and 4 weeks treated with 
simvastatin     
 
Duration 
(week) Groups 
Total 
Bilirubin 
Mg/dL 
Total 
Protein 
g/dL 
Albumin 
g/dL 
Globulin 
g/dL 
Alb/Glb 
ratio 
2 B 
C 
D 
E 
0.01±0.11 
0.02±0.15 
0.03±0.17 
0.03±0.19 
1.8±13 
1.9±1.3 
2.0±1.4 
2.0±1.4 
0.8±0.9 
1.01±1.0 
1.0±1.0 
0.9±0.9 
0.96±0.9 
0.92±0.9 
1.0±1.0 
1.0±1.0 
0.8±1 
1.0±1.1 
1.0±1.0 
0.9±0.9 
4 B 
C 
D 
E 
0.05±0.2 
0.05±0.2 
0.05±0.2 
0.05±0.2 
1.8±1.3 
1.9±1.3 
1.7±1.3 
1.6±1.2 
1.0±1.1 
0.9±0.9 
1.0±1.0 
0.6±0.8 
0.8±0.9 
0.9±0.9 
0.7±0.8 
0.9±0.9 
1.2±1.2 
1.0±1.0 
1.4±1.2 
0.7±0.8 
 
Values are presented as Means ± SE (standard errors)  
Groups: 
 (B):  Fed cholesterol-containing diet 1% only. 
(C):  Fed cholesterol-containing diet 1% &received 10 mg/kg Simvastatin. 
(D):  Fed cholesterol-containing diet 1%& received 40 mg/kg Simvastatin. 
(E):  Fed cholesterol-containing diet 1%& received 80 mg/kg Simvastatin 
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3.6 Hematological findings 
 3.6.1 Red Blood Cell Counts (RBCs) 
The effect of simvastatin on hematological parameters is 
presented in table (6). 
          There were no significant differences in Red Blood Cell Counts 
between treated groups (C, D, and E) compared to control group (B) 
after 4 weeks of administration of Simvastatin. 
3.6.2 White Blood Cell Counts (WBCs)  
There was a significant decrease (P<0.05) in WBCs in group 
(D) received 40mg/kg Simvastatin (8.100±1.4  × 10mm³) compared to 
control (B) (16.733±2.4)10mm³) after 4 weeks of administration of 
Simvastatin in hypercholesterolemic rats. However the WBCs showed 
no significant changes in groups (C and E) received (10, 40mg/kg) 
Bwt respectively compared to control (B). 
3.6.3 Hemoglobin concentrations (Hb) 
There was a significant decrease (P<0.05) in (Hb) concentration 
in group (E) received 80mg/kg Bwt (7.850±1.4 ×10g/dL) compared to 
control (B) (11.450±1.7 g/dL), however, there were no significant 
differences in hemoglobin concentration in groups (C and D) 
compared to control (B). 
3.6.4 Packed Cell Volume (PCV %) 
There was a significant decrease (P<0.05) on PCV value in 
group (E) by (27.10±2.6) compared to control (B) (38.48±3.1) after 4 
weeks. However, there were no significant changes in groups (C and 
D) compared to control (B) after 4 weeks of experiment. 
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Table (6): Mean changes in hematological parameters in an induced 
hypercholeserolemic after 4 weeks rats treated with 
Simvastatin 
 
 
Values are presented as Means ± SE (standard errors) 
 Significance             *    (P<0.05)    
Groups: 
(B): fed cholesterol-containing diet 1% only. 
(C): fed cholesterol-containing diet 1% &received 10 mg/kg simvastatin. 
(D): fed cholesterol-containing diet 1%& received 40 mg/kg simvastatin. 
(E): fed cholesterol-containing diet 1%& received 80 mg/kg simvastatin. 
RBCs: Red Blood Cell Counts        WBCs: White Blood Cell Counts 
Hb: Hemoglobin concentrations     PCV%: Packed Cell Volume% 
 
 
 
 
 
 
 
 
 
Duration Group RBCs ×10mm6 
WBCs×      
10mm³ Hb g/dL PCV % 
Platelets     
mg/dL 
4 B 6.7525±1.3 15.700±2.0 11.450±1.7 38.48±3.1 878.75±14.8
C 5.8066±1.4 16.733±2.4 11.033±1.9 36.53±3.5 935.33±17.7
D 4.8675±1.1 8.100±1.4* 9.425±1.5 30.43±2.8 694.25±13.2
E 4.1175±1.0 14.850±1.9 7.850±1.4* 27.10±2.6* 870.75±14.8
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3.6.5 Platelets 
There were no significant changes in groups (C, D and E) 
compared to control (B) after 4 weeks of experiment. 
3.7 Histopathological Finding 
In group (B) which was fed cholesterol 1% the liver showed 
haemorrhage, disorganization and vaculation of sinusoid fig (3). The 
muscle showed fragmentation , necrosis , hyalinosis,  muscle banding 
separated each other and muscle fiber loss there nucleus (4). 
In the group treated with 10mg\kg Bwt the liver was showed  
vaculation, muscle banding separated. 
In the group treated with 40mg\kg Bwt the liver was showed 
dilatation of sinusoid. Muscle showed fragmentation of muscle (5). 
In the group treated with 08mg\kg Bwt the liver was dilatation 
of sinusoid and congestion of the central vein (6) 
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Fig (3): Liver  from rats fed (1% cholesterol diet).Notice, hemorrhage, 
disorganization of hepatic plates and vaculization. 
Haemotoxaline & Eusin(400 X ) 
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Fig. (4): Muscle from rats fed (1% cholesterol diet). Notice, 
fragmentation, hyalinization, necrosis and loss of muscle 
fibers nuclei. Haemotoxaline &Eusin(100 X ) 
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Fig (5): Muscle from rats received 40mg\kg Bwt Simvastatin. Notice 
less fragmented muscle fibers. Haemotoxaline &Eusin (400 
X) 
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Fig. (6): Liver from rats received 80mg\kg Bwt Simvastatin. Notice, 
dilatation of sinusoids and congestion of the central vein. 
Haemotoxaline &Eusin(400 X ) 
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CHAPTER FOUR 
DISCUSSION 
 
4.1 Induction of hypercholesterolemia and body weight 
In this study, the addition of 1%cholesterol in diet for 
2weeks significantly increased rat’s body weight, and plasma 
cholesterol to level up to 193.33 mg/dL, this finding is on line 
with Son et al., (2007) who found that, hypercholesterolemia can be 
induced on Wistar rats when they were fed a diet supplemented with 
cholesterol, the plasma cholesterol and body weight were significantly 
elevated in rats received a 1% cholesterol diet for 8 weeks. Also Getz 
et al. (2006) found that, Lipid-enriched      diets are often used to 
induce or accelerate the rate of induction of persistent 
hypercholesterolemia in mice to levels > or approximately 300 
mg/dL, as well as the protein source has been shown to influence 
lipoprotein level. 
Birkner et al. (2009) showed that experimental hyper-
cholesterolemia has been induced in the animals with the diet 
enriched with 0.5 and 2 g% of cholesterol/100 g of fodder/24 
hours. 
4.2Total cholesterol (T.C) 
In this study, Simvastatin had a  hypocholesterolemic effect 
in  treated groups, it reduced cholesterol by 24.75%, 31.34%, 
93.46% respectively, this agree with, Ragino (2008)  
experimentally in rabbit  hypercholesterolemia. He found that at 
doses of 40, 66.5, and 100 mg/kg/day reduced total blood 
cholesterol by 36, 38, and 47% (P<0.05), respectively, after 20-
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day. Also ( Fraunberger et al.,  2009) found that simvastatin reduced 
circulating total-cholesterol and LDL- cholesterol levels by 68 % and 
76 %, respectively. 
4.2.1 Low density lipoproteins 
The current study, showed that simvastatin had a significant 
effect on LDL-c .This result is on line with (Ballantyne et al., 
2008) who found that treatment with simvastatin reduced total 
cholesterol, total triglycerides and low-density lipoprotein cholesterol 
He also statin therapy alters the relationship between 
apolipoprotein B and low-density lipoprotein cholesterol and non-
high-density lipoprotein cholesterol targets in high-risk patients. 
  Youssef, et al. (2004) repored that there was a significant 
reduction in T.C L and LDL cholesterol.  
4.3 Serum constituents 
4.3.1 Creatine kinase activity (CK) 
In the present study, the activity of serum creatine kinase 
showed a significant increase in treated groups with simvastatin 
compared to control; this result agree with Chan, et al. (2005) who 
found that simvastatin was generally associated with high elevation 
and mild to moderate elevation of (creatine kinase) CK levels. 
Myopathy is the most serious, dose dependent adverse reaction 
of statins and may lead to rhabdomyolysis and death. Clinical 
symptoms are muscle pain, weakness and muscle cramps, main 
laboratory finding is an increase in serum creatine kinase (CK). If 
myopathy symptoms are present or CK levels are greater than 5 times 
the upper limits of normal, statin therapy should be discontinued. In 
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case of an asymptomatic CK increase below 5 times the upper limits 
of normal, therapy can be continued with CK monitoring (Rasche-
Schürmann et al., 2008) 
4.3.2 Liver Transaminases (ALT and AST) 
The present study found that there was a significant changes in 
liver transaminiases on high dose simvastatin therapy, this result agree 
with, (Cohen et al. 2006) that  demonstrated asymptomatic increases 
of liver enzymes the normal,have been reported in patients treated 
with simvastatin. 
Dale et al. ( 2007) found that more aggressive statin therapy 
increases the incidence of transaminase elevations. 
On the other hand, (Dold et al., 2009) who found that 
administration of 0.2 mg. kg (-1) simvastatin decreased  liver enzymes 
ALT and AST by 87% and 83%, respectively, in mice.  
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CONCLUSION 
 
In this study, it is confirmed that Simvastatin posseses a potent 
effect on Serum cholesterol and LDL-cholesterol and had undesirable 
effects on liver enzymes when it was given in high doses for along 
period of time “dose dependent”  
Further research may be done to confirm this finding using 
different doses. 
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